These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo. Tang X; Zhu H; Sun L; Hou W; Cai S; Zhang R; Liu F Int J Nanomedicine; 2014; 9():5403-13. PubMed ID: 25473279 [TBL] [Abstract][Full Text] [Related]
24. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp. Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510 [TBL] [Abstract][Full Text] [Related]
25. Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation. Gupta PK; Jaiswal AK; Kumar V; Verma A; Dwivedi P; Dube A; Mishra PR Mol Pharm; 2014 Mar; 11(3):951-63. PubMed ID: 24495144 [TBL] [Abstract][Full Text] [Related]
26. Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans. Zia Q; Khan AA; Swaleha Z; Owais M Int J Nanomedicine; 2015; 10():1769-90. PubMed ID: 25784804 [TBL] [Abstract][Full Text] [Related]
27. Amphotericin B nanohydrogel ocular formulation using alkyl glyceryl hyaluronic acid: Formulation, characterization, and in vitro evaluation. Banshoya K; Fujita C; Hokimoto Y; Ohnishi M; Inoue A; Tanaka T; Kaneo Y Int J Pharm; 2021 Dec; 610():121061. PubMed ID: 34481008 [TBL] [Abstract][Full Text] [Related]
28. Reformulation of Fungizone by PEG-DSPE Micelles: Deaggregation and Detoxification of Amphotericin B. Alvarez C; Shin DH; Kwon GS Pharm Res; 2016 Sep; 33(9):2098-106. PubMed ID: 27198671 [TBL] [Abstract][Full Text] [Related]
29. Linolenic acid-modified MPEG-PEI micelles for encapsulation of amphotericin B. Xu H; Teng F; Zhou F; Zhu L; Wen Y; Feng R; Song Z Future Med Chem; 2019 Oct; 11(20):2647-2662. PubMed ID: 31621420 [No Abstract] [Full Text] [Related]
31. Antifungal activity of amphotericin B conjugated to carbon nanotubes. Benincasa M; Pacor S; Wu W; Prato M; Bianco A; Gennaro R ACS Nano; 2011 Jan; 5(1):199-208. PubMed ID: 21141979 [TBL] [Abstract][Full Text] [Related]
32. Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B Singh A; Yadagiri G; Parvez S; Singh OP; Verma A; Sundar S; Mudavath SL Mater Sci Eng C Mater Biol Appl; 2020 Dec; 117():111279. PubMed ID: 32919641 [TBL] [Abstract][Full Text] [Related]
33. Enhancing Safety and Efficacy by Altering the Toxic Aggregated State of Amphotericin B in Lipidic Nanoformulations. Das S; Devarajan PV Mol Pharm; 2020 Jun; 17(6):2186-2195. PubMed ID: 32324420 [TBL] [Abstract][Full Text] [Related]
34. Induction of interleukin-1beta, tumour necrosis factor-alpha and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan. Falk R; Hacham M; Nyska A; Foley JF; Domb AJ; Polacheck I J Antimicrob Chemother; 2005 May; 55(5):713-20. PubMed ID: 15814605 [TBL] [Abstract][Full Text] [Related]
35. Amphotericin B formulations: a comparative review of efficacy and toxicity. Hamill RJ Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001 [TBL] [Abstract][Full Text] [Related]
36. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation. Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313 [TBL] [Abstract][Full Text] [Related]
37. Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study. Mohamed HA; Radwan RR; Raafat AI; Ali AE Drug Deliv Transl Res; 2018 Feb; 8(1):191-203. PubMed ID: 29280061 [TBL] [Abstract][Full Text] [Related]
38. NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency. Burgess BL; He Y; Baker MM; Luo B; Carroll SF; Forte TM; Oda MN Int J Nanomedicine; 2013; 8():4733-43. PubMed ID: 24379661 [TBL] [Abstract][Full Text] [Related]
39. Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B. Iman M; Huang Z; Szoka FC; Jaafari MR Int J Pharm; 2011 Apr; 408(1-2):163-72. PubMed ID: 21277963 [TBL] [Abstract][Full Text] [Related]
40. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro. Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]